Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biofrontera (BFRI) Operating Expenses: 2020-2025

Historic Operating Expenses for Biofrontera (BFRI) over the last 5 years, with Sep 2025 value amounting to $13.3 million.

  • Biofrontera's Operating Expenses fell 5.05% to $13.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.8 million, marking a year-over-year increase of 0.11%. This contributed to the annual value of $54.5 million for FY2024, which is 3.91% down from last year.
  • As of Q3 2025, Biofrontera's Operating Expenses stood at $13.3 million, which was down 5.97% from $14.1 million recorded in Q2 2025.
  • In the past 5 years, Biofrontera's Operating Expenses registered a high of $20.4 million during Q3 2021, and its lowest value of $8.0 million during Q3 2022.
  • For the 3-year period, Biofrontera's Operating Expenses averaged around $13.8 million, with its median value being $14.0 million (2024).
  • Per our database at Business Quant, Biofrontera's Operating Expenses spiked by 265.24% in 2021 and then tumbled by 61.05% in 2022.
  • Over the past 5 years, Biofrontera's Operating Expenses (Quarterly) stood at $11.0 million in 2021, then surged by 42.69% to $15.8 million in 2022, then fell by 8.27% to $14.5 million in 2023, then decreased by 1.31% to $14.3 million in 2024, then fell by 5.05% to $13.3 million in 2025.
  • Its Operating Expenses stands at $13.3 million for Q3 2025, versus $14.1 million for Q2 2025 and $13.1 million for Q1 2025.